FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ATP8A1-CRMP1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ATP8A1-CRMP1
FusionPDB ID: 8230
FusionGDB2.0 ID: 8230
HgeneTgene
Gene symbol

ATP8A1

CRMP1

Gene ID

10396

1400

Gene nameATPase phospholipid transporting 8A1collapsin response mediator protein 1
SynonymsATPASEII|ATPIA|ATPP2CRMP-1|DPYSL1|DRP-1|DRP1|ULIP-3
Cytomap

4p13

4p16.2

Type of geneprotein-codingprotein-coding
Descriptionphospholipid-transporting ATPase IAATPase IIATPase class I type 8A member 1ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1P4-ATPase flippase complex alpha subunit ATP8A1aminophospholipid translocasechromaffin granule ATPase dihydropyrimidinase-related protein 1dihydropyrimidinase-like 1inactive dihydropyrimidinaseunc-33-like phosphoprotein 3
Modification date2020032920200320
UniProtAcc

Q9Y2Q0

Main function of 5'-partner protein: FUNCTION: Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids (PubMed:31416931). Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. In vitro, its ATPase activity is selectively and stereospecifically stimulated by phosphatidylserine (PS) (PubMed:31416931). The flippase complex ATP8A1:TMEM30A seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the plasma membrane (By similarity). Acts as aminophospholipid translocase at the plasma membrane in neuronal cells (By similarity). {ECO:0000250|UniProtKB:P70704, ECO:0000269|PubMed:31416931}.

Q14194

Main function of 5'-partner protein: FUNCTION: Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton (PubMed:25358863). Plays a role in axon guidance (PubMed:25358863). During the axon guidance process, acts downstream of SEMA3A to promote FLNA dissociation from F-actin which results in the rearrangement of the actin cytoskeleton and the collapse of the growth cone (PubMed:25358863). Involved in invasive growth and cell migration (PubMed:11562390). May participate in cytokinesis (PubMed:19799413). {ECO:0000269|PubMed:11562390, ECO:0000269|PubMed:19799413, ECO:0000269|PubMed:25358863}.
Ensembl transtripts involved in fusion geneENST idsENST00000264449, ENST00000381668, 
ENST00000510289, 
ENST00000511535, 
ENST00000512574, ENST00000324989, 
ENST00000397890, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score9 X 13 X 7=8196 X 7 X 6=252
# samples 138
** MAII scorelog2(13/819*10)=-2.65535182861255
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(8/252*10)=-1.65535182861255
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ATP8A1 [Title/Abstract] AND CRMP1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ATP8A1 [Title/Abstract] AND CRMP1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ATP8A1(42626553)-CRMP1(5844888), # samples:3
Anticipated loss of major functional domain due to fusion event.ATP8A1-CRMP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP8A1-CRMP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP8A1-CRMP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP8A1-CRMP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneCRMP1

GO:1904530

negative regulation of actin filament binding

25358863



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:42626553/chr4:5844888)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ATP8A1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CRMP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000381668ATP8A1chr442626553-ENST00000324989CRMP1chr45844888-26895952321692486
ENST00000381668ATP8A1chr442626553-ENST00000397890CRMP1chr45844888-26705952321692486
ENST00000264449ATP8A1chr442626553-ENST00000324989CRMP1chr45844888-26775832201680486
ENST00000264449ATP8A1chr442626553-ENST00000397890CRMP1chr45844888-26585832201680486
ENST00000381668ATP8A1chr442626552-ENST00000324989CRMP1chr45844888-26895952321692486
ENST00000381668ATP8A1chr442626552-ENST00000397890CRMP1chr45844888-26705952321692486
ENST00000264449ATP8A1chr442626552-ENST00000324989CRMP1chr45844888-26775832201680486
ENST00000264449ATP8A1chr442626552-ENST00000397890CRMP1chr45844888-26585832201680486

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000381668ENST00000324989ATP8A1chr442626553-CRMP1chr45844888-0.0022465180.99775344
ENST00000381668ENST00000397890ATP8A1chr442626553-CRMP1chr45844888-0.0023274040.9976726
ENST00000264449ENST00000324989ATP8A1chr442626553-CRMP1chr45844888-0.0020508940.99794906
ENST00000264449ENST00000397890ATP8A1chr442626553-CRMP1chr45844888-0.0021304940.9978695
ENST00000381668ENST00000324989ATP8A1chr442626552-CRMP1chr45844888-0.0022465180.99775344
ENST00000381668ENST00000397890ATP8A1chr442626552-CRMP1chr45844888-0.0023274040.9976726
ENST00000264449ENST00000324989ATP8A1chr442626552-CRMP1chr45844888-0.0020508940.99794906
ENST00000264449ENST00000397890ATP8A1chr442626552-CRMP1chr45844888-0.0021304940.9978695

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP8A1-CRMP1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ATP8A1chr442626552CRMP1chr45844888583121LAVAAIKEIIEDIEQKRILEMGITGP
ATP8A1chr442626552CRMP1chr45844888595121LAVAAIKEIIEDIEQKRILEMGITGP
ATP8A1chr442626553CRMP1chr45844888583121LAVAAIKEIIEDIEQKRILEMGITGP
ATP8A1chr442626553CRMP1chr45844888595121LAVAAIKEIIEDIEQKRILEMGITGP

Top

Potential FusionNeoAntigen Information of ATP8A1-CRMP1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP8A1-CRMP1_42626552_5844888.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP8A1-CRMP1chr442626552chr45844888583HLA-B14:01IEQKRILEM0.99840.78011221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B14:02IEQKRILEM0.99840.78011221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:01IEQKRILEM0.99490.92511221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B44:03IEQKRILEM0.99310.82371221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B15:03IEQKRILEM0.91420.78821221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B39:13IEQKRILEM0.73320.93841221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B41:01IEDIEQKRI0.570.7614918
ATP8A1-CRMP1chr442626552chr45844888583HLA-B40:06IEQKRILEM0.9990.51291221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B14:03IEQKRILEM0.95460.881221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B39:08IEQKRILEM0.88820.7831221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B39:08IEDIEQKRI0.61380.6716918
ATP8A1-CRMP1chr442626552chr45844888583HLA-B39:08IEDIEQKRIL0.9740.7324919
ATP8A1-CRMP1chr442626552chr45844888583HLA-B08:12DIEQKRIL0.9920.50351119
ATP8A1-CRMP1chr442626552chr45844888583HLA-B40:04IEQKRILEM0.99870.6191221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:04IEQKRILEM0.99630.93311221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:07IEQKRILEM0.99620.89971221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:06IEQKRILEM0.9960.93181221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:08IEQKRILEM0.9960.9031221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:05IEQKRILEM0.99490.92511221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B44:26IEQKRILEM0.99310.82371221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B44:13IEQKRILEM0.99310.82371221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B44:07IEQKRILEM0.99310.82371221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:03IEQKRILEM0.99280.91941221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:11IEQKRILEM0.95130.92521221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B15:53IEQKRILEM0.89550.91371221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B48:02IEQKRILEM0.86610.91221221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B39:02IEQKRILEM0.76270.94131221
ATP8A1-CRMP1chr442626552chr45844888583HLA-B18:03DIEQKRILEM0.64220.95951121

Top

Potential FusionNeoAntigen Information of ATP8A1-CRMP1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP8A1-CRMP1_42626552_5844888.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0301IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0301AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0301AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0301KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0303IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0303AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0305IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0307IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0307AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0307AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0307KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0310IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0310AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0310AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0310KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0313IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0313AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0313AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0313KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0315IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0315AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0315AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0315KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0318IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0318AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0318AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0318KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0320IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0320AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0320AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0320KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0322IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0322AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0322AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0322KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0324IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0326IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0326AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0326AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0326KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0328IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0328AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0328AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0328KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0330IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0330AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0330AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0330KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0332IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0332AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0332AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0332KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0334IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0334AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0334AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0334KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0336IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0336AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0336AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0336KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0340IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0342IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0342AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0342AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0342KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0344IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0344AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0344AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0344KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0346IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0346AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0346AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0346KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0348IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0348AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0348AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0348KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0350IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0350AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0350AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0350KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0352IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0352AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0352AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0352KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0354IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0354AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0354AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-0354KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1107IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1107AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1107AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1107KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1219IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1219KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1220IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1220KEIIEDIEQKRILEM621
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1221IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1476IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1476AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1476AAIKEIIEDIEQKRI318
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1479IKEIIEDIEQKRILE520
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1479AIKEIIEDIEQKRIL419
ATP8A1-CRMP1chr442626552chr45844888583DRB1-1479AAIKEIIEDIEQKRI318

Top

Fusion breakpoint peptide structures of ATP8A1-CRMP1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4199KEIIEDIEQKRILEATP8A1CRMP1chr442626552chr45844888583

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP8A1-CRMP1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4199KEIIEDIEQKRILE-7.15543-7.26883
HLA-B14:023BVN4199KEIIEDIEQKRILE-4.77435-5.80965
HLA-B52:013W394199KEIIEDIEQKRILE-6.80875-6.92215
HLA-B52:013W394199KEIIEDIEQKRILE-4.20386-5.23916
HLA-A11:014UQ24199KEIIEDIEQKRILE-7.5194-8.5547
HLA-A11:014UQ24199KEIIEDIEQKRILE-6.9601-7.0735
HLA-A24:025HGA4199KEIIEDIEQKRILE-7.52403-7.63743
HLA-A24:025HGA4199KEIIEDIEQKRILE-5.82433-6.85963
HLA-B27:056PYJ4199KEIIEDIEQKRILE-3.28285-4.31815
HLA-B44:053DX84199KEIIEDIEQKRILE-5.91172-6.94702
HLA-B44:053DX84199KEIIEDIEQKRILE-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ATP8A1-CRMP1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ATP8A1-CRMP1chr442626552chr458448881119DIEQKRILGATATTGAACAAAAGCGGATCCTG
ATP8A1-CRMP1chr442626552chr458448881121DIEQKRILEMGATATTGAACAAAAGCGGATCCTGGAGATG
ATP8A1-CRMP1chr442626552chr458448881221IEQKRILEMATTGAACAAAAGCGGATCCTGGAGATG
ATP8A1-CRMP1chr442626552chr45844888918IEDIEQKRIATAGAAGATATTGAACAAAAGCGGATC
ATP8A1-CRMP1chr442626552chr45844888919IEDIEQKRILATAGAAGATATTGAACAAAAGCGGATCCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ATP8A1-CRMP1chr442626552chr45844888318AAIKEIIEDIEQKRIGCAGCTATCAAAGAGATAATAGAAGATATTGAACAAAAGCGGATC
ATP8A1-CRMP1chr442626552chr45844888419AIKEIIEDIEQKRILGCTATCAAAGAGATAATAGAAGATATTGAACAAAAGCGGATCCTG
ATP8A1-CRMP1chr442626552chr45844888520IKEIIEDIEQKRILEATCAAAGAGATAATAGAAGATATTGAACAAAAGCGGATCCTGGAG
ATP8A1-CRMP1chr442626552chr45844888621KEIIEDIEQKRILEMAAAGAGATAATAGAAGATATTGAACAAAAGCGGATCCTGGAGATG

Top

Information of the samples that have these potential fusion neoantigens of ATP8A1-CRMP1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVATP8A1-CRMP1chr442626552ENST00000264449chr45844888ENST00000324989TCGA-25-1324

Top

Potential target of CAR-T therapy development for ATP8A1-CRMP1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneATP8A1chr4:42626552chr4:5844888ENST00000264449-43666_861211150.0TransmembraneHelical
HgeneATP8A1chr4:42626552chr4:5844888ENST00000264449-43693_1151211150.0TransmembraneHelical
HgeneATP8A1chr4:42626552chr4:5844888ENST00000381668-43766_861211165.0TransmembraneHelical
HgeneATP8A1chr4:42626552chr4:5844888ENST00000381668-43793_1151211165.0TransmembraneHelical
HgeneATP8A1chr4:42626553chr4:5844888ENST00000264449-43666_861211150.0TransmembraneHelical
HgeneATP8A1chr4:42626553chr4:5844888ENST00000264449-43693_1151211150.0TransmembraneHelical
HgeneATP8A1chr4:42626553chr4:5844888ENST00000381668-43766_861211165.0TransmembraneHelical
HgeneATP8A1chr4:42626553chr4:5844888ENST00000381668-43793_1151211165.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ATP8A1-CRMP1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ATP8A1-CRMP1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource